Key board statistics on workplace skin cancer prevention.

When a health condition will touch two-thirds of your people, it stops being an HR program and starts being a workforce-continuity issue the board owns alongside attrition and absenteeism.

Each late-stage diagnosis carries six- to seven-figure downstream costs once you load treatment leave, replacement labour and dependant support. Mortality data is the financial leading indicator boards keep underweighting.

When a single disease costs the system $1.7B annually, underwriters re-price the exposure. CFOs who pre-empt that re-pricing with a documented prevention program protect their premium trajectory.

UV is the most prevalent carcinogen in our workforce yet sits below noise and dust in most board safety dashboards. Boards should ask why a hazard touching 1-in-5 workers is not on the principal-hazard register.

A 5-to-10× dose differential turns an average risk into a near-certainty over a career. Enterprise-wide wellbeing benefits will not move this curve — only role-targeted controls will.

Accepted-claim totals understate true exposure by an order of magnitude once latency, attribution and under-reporting are corrected. Boards should treat the published figure as a floor, not a ceiling.

A 73-point survival gap is also the cost gap between a $1k excision and a multi-year systemic treatment pathway. No other workplace health intervention has this kind of unit economics.

With workforce participation extending past 65, latent UV damage accumulated decades ago is now presenting on payroll. Boards are inheriting a liability built across a working lifetime.

Boards funding melanoma-only screening will miss the 95% of lesions their workforce actually presents with. The right design is high-volume SCC/BCC triage with melanoma escalation built in.